Figure 1: Potential points of integration of RE into the treatment pathway of patients with liver-only or liver-dominant unresectable colorectal liver metastases. Figure adapted from reference [17]. The shaded boxes show clinical trials testing RE with systemic therapy. Abbreviations used: CAPIRI, capecitabine and irinotecan; CAPOX, cetuximab, oxaliplatin and capecitabine; FCCC, Fox Chase Cancer Center; 5-FU, 5-fluorouracil; FOLFIRI, 5-fluorouracil, leucovorin and irinotecan; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; RE, radioembolization; RLCC, Robert H. Lurie Comprehensive Cancer Center. An example of a patient registry in development is: http://www.sirtex.com/content.cfm?sec=usa&MenuID=1120&ID=F4CCC1C2